Cardiac Arrhythmias: New Therapeutic Drugs and Devices: Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984 / Edition 1

Cardiac Arrhythmias: New Therapeutic Drugs and Devices: Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984 / Edition 1

by J. Morganroth
     
 

ISBN-10: 0898387167

ISBN-13: 9780898387162

Pub. Date: 04/30/1985

Publisher: Springer US

Product Details

ISBN-13:
9780898387162
Publisher:
Springer US
Publication date:
04/30/1985
Series:
Developments in Cardiovascular Medicine Series, #47
Edition description:
1985
Pages:
356
Product dimensions:
6.10(w) x 9.25(h) x 0.03(d)

Table of Contents

I Basic Considerations.- 1 What animal models are useful in selecting new antiarrhythmic drugs?.- 2 How to test for antiarrhythmic drugs.- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients?.- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs?.- Panel Discussion: Basic considerations.- II Status of Specific Antiarrhythmic Agents.- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — efficacy in the treatment of ventricular arrhythmias: current status and controversies.- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents.- 7 Class IC antiarrhythmic agents: status — 1984.- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias.- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol.- Panel Discussion: Status of specific antiarrhythmic agents.- III Special Considerations and FDA Standards.- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice.- 11 Use of a computer in the new drug evaluation process.- 12 Sudden cardiac death — failure or effect of antiarrhythmic drug therapy?.- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs.- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models?.- Panel Discussion: Special considerations and FDA standards.- IV New Antiarrhythmic Devices.- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic?.- 16 Pacing for ventricular tachycardia.- 17 Termination of ventricular tachycardia by transvenous cardioversion.- 18 The automatic implantable cardioverter/defibrillator.- 19 New antiarrhythmia devices — FDA’s requirements for effectiveness.- Panel Discussion: New antiarrhythmic devices.- V Evaluation Of Atrial Arrhythmias.- 20 Study designs to evaluate atrial arrhythmias are easy.- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection.- 22 Approaches to drug selection and serial drug testing.- Panel Discussion: Evaluation of atrial arrhythmias.- Participants.

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >